ELDN Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. (ELDN) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is a loss of $0.20 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -1.7% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS.
Sector
Healthcare
Industry
Biotechnology